Trials Sponsors Conditions Drugs Pricing

Conditions

Malignant Mesothelioma

Keywords

localized malignant mesothelioma

Interventions

chemotherapyDrug

adjuvant therapyProcedure

conventional surgeryProcedure

neoadjuvant therapyProcedure

radiation therapyRadiation

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically and immuno-histochemically confirmed malignant mesothelioma * Resectable disease (T1-3, N0-1, M0) with no distant metastases * Eligible to undergo extra-pleural pneumonectomy based on British Thoracic Society guidelines PATIENT CHARACTERISTICS: Performance status * WHO 0-1 Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Normal renal function Cardiovascular * Ejection fraction ≥ 40% Pulmonary * Predicted post-operative FEV\_1 ≥ 40% * Predicted post-operative DLCO ≥ 40% * No significant pulmonary hypertension Other * No physical or personal condition that would preclude ability to undergo chemotherapy or post-operative radiotherapy * No physical or personal condition that would preclude ability to comply with follow-up requirements PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Institute of Cancer Research, United Kingdom
Otherlead

Study Sites (17)

Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

Birmingham, England, B15 2TH, United Kingdom

Birmingham Heartlands Hospital

Birmingham, England, B9 5SS, United Kingdom

Bristol Royal Infirmary

Bristol, England, BS2 8HW, United Kingdom

Queen's Hospital

Burton-on-Trent, England, DE13 0RB, United Kingdom

Addenbrooke's Hospital

Cambridge, England, CB2 2QQ, United Kingdom

Papworth Hospital

Cambridge, England, CB3 8RE, United Kingdom

Ipswich Hospital

Ipswich, England, IP4 5PD, United Kingdom

MeSH Terms

Conditions

Mesothelioma, Malignant

Interventions

Drug TherapyChemotherapy, AdjuvantNeoadjuvant TherapyRadiotherapy

Condition Hierarchy (Ancestors)

MesotheliomaAdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, MesothelialLung NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms

Study Officials

Clare Peckitt
Institute of Cancer Research, United Kingdom
STUDY CHAIR

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Purpose: TREATMENT
Sponsor Type: OTHER

Study Record Dates

First Submitted

November 11, 2005

First Posted

November 15, 2005

Study Start

May 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2011

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (17)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (17)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations